Research projects from five biopharmaceutical companies in the United States, Canada and Israel comprise the 2013 first half of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants’ research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson’s disease through the pipeline of drug development and eventually into patients’ hands.

To read more on the selected participants, and all MJFF awardees chosen for the Partnering Program thus far, visit the Partnering Program Web page.